Avilar Therapeutics Appoints Leslie Meltzer, Ph.D. as Chief Executive Officer
PRIVATEOct 05, 2026
Position
Chief Executive Officer
Company
Avilar Therapeutics
Leslie Meltzer, Ph.D.
WalthamSoftware
Description
Avilar Therapeutics has appointed Leslie Meltzer, Ph.D. as its new Chief Executive Officer. The company continues to advance its lead therapy for preeclampsia.
Company Information
Company
Avilar Therapeutics
Location
Waltham, Massachusetts, United States
About
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
Fundz sees it the moment Avilar Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
WalthamSoftware